How have IRON and RXRX total returns compared?

Over the past 5 years, IRON delivered 10.70% and RXRX delivered -25.86% annualized total return. Past performance doesn't predict future results.

Disc Medicine, Inc. (IRON) vs Recursion Pharmaceuticals, Inc. (RXRX)

A side-by-side comparison of Disc Medicine, Inc. and Recursion Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

IRON

Disc Medicine, Inc.

$2.37B

$61.65HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

RXRX

Recursion Pharmaceuticals, Inc.

$2.43B

$4.63HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — IRON vs RXRX

growth of $100 · dividends reinvested · last 5y

IRON -45.1% (-11.3%/yr)RXRX -73.4% (-23.3%/yr)IRON compounded faster over this window

IRON RXRX

IRON vs RXRX: by the numbers

•RXRX is the larger company ($2.43B vs $2.37B market cap).
•Both run net losses; IRON's is the smaller (0.00% vs -945.92% net margin).

Metrics side by side

Valuation

Metric	IRON	RXRX
P/S ratio	N/A	44.29
P/B ratio	3.67	2.65

Profitability

Metric	IRON	RXRX
Gross margin	0.00%	-61.96%
Operating margin	0.00%	-867.87%
Net margin	0.00%	-945.92%
ROE	-38.17%	-56.71%
ROIC	-38.21%	-49.78%

Growth (annualized)

Metric	IRON	RXRX
Revenue CAGR (5Y)	N/A	45.50%
Total return CAGR (5Y)	10.70%	-25.86%

Frequently asked

How have IRON and RXRX total returns compared?: Over the past 5 years, IRON delivered 10.70% and RXRX delivered -25.86% annualized total return. Past performance doesn't predict future results.

Go deeper

Full IRON analysis Full RXRX analysis Interactive comparison tool

Dig into the metrics

Disc Medicine ROE Recursion Pharmaceuticals ROE Disc Medicine operating margin Recursion Pharmaceuticals operating margin Disc Medicine revenue growth Recursion Pharmaceuticals revenue growth Disc Medicine free cash flow Recursion Pharmaceuticals free cash flow

Disc Medicine & Recursion Pharmaceuticals appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.